Business & Finance

Critical Therapeutics reports preliminary operating results for fourth quarter of 2006

Published in Healthcare Finance, Tax and Law Weekly, February 7th, 2007

Critical Therapeutics, Inc. (CRTX) announced that preliminary results indicate continued incremental growth in unit sales of Zyflo (zileuton tablets) in the fourth quarter of 2006, compared with the third quarter of 2006, despite a reduced number of sales representatives.

In addition, based on preliminary results, the company anticipates net cash expenditures in the fourth quarter will be approximately 23% below its previous fourth quarter net cash expenditure guidance.

For the three months ended December 31, 2006, the company expects to report revenue from Zyflo sales of between $1.9 million and $2.1 million based on prescriptions filled. Sales...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-02-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry